(This story is from our new Health Tech newsletter. If you’d like to sign up, just click here.)
Venture capital, private and non-profit investors who spoke at a panel in New York this week laid out their investment priorities in health tech companies that use AI, saying they’re interested in how artificial intelligence can improve behavioral health and drug development.
Andreessen Horowitz investment partner Daisy Wolf told the audience of a panel at Cornell Tech’s HealthNext Summit on Tuesday that she believes AI is going to drive drug discovery and health diagnosis so that people can have a doctor in their pockets. AI can also save clinicians time and boost efficiency by getting rid of frustrating minutiae in healthcare, she added.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.